Donald S Kaufman

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi request reprint Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 21-2004. A 63-year-old man with metastatic prostate carcinoma refractory to hormone therapy
    Donald S Kaufman
    Division of Medical Oncology, Department of Medicine, Massachusetts General Hospital, USA
    N Engl J Med 351:171-8. 2004
  2. doi request reprint Bladder cancer
    Donald S Kaufman
    Department of Medicine, the Claire and John Bertucci Center for Genitourinary Cancers, Massachusetts General Hospital, Boston, MA 02114, USA
    Lancet 374:239-49. 2009
  3. doi request reprint Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy
    Donald S Kaufman
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Urology 73:833-7. 2009
  4. pmc Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06
    Jason A Efstathiou
    Department of Radiation Oncology, Massachusetts General Hospital, 100 Blossom St, Cox 3, Boston, MA 02114, USA
    J Clin Oncol 27:4055-61. 2009
  5. doi request reprint Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase
    Timur Mitin
    Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114, USA
    Lancet Oncol 14:863-72. 2013
  6. doi request reprint Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience
    Jason A Efstathiou
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Eur Urol 61:705-11. 2012
  7. doi request reprint The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
    Jennifer Y Wo
    Harvard Radiation Oncology Programm, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    BJU Int 104:179-83. 2009
  8. doi request reprint Nomograms predicting response to therapy and outcomes after bladder-preserving trimodality therapy for muscle-invasive bladder cancer
    John J Coen
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Int J Radiat Oncol Biol Phys 86:311-6. 2013
  9. doi request reprint Bladder preservation: optimizing radiotherapy and integrated treatment strategies
    Raymond H Mak
    Department of Radiation, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    BJU Int 102:1345-53. 2008
  10. ncbi request reprint Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up
    William K Oh
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Urology 62:99-104. 2003

Detail Information

Publications32

  1. ncbi request reprint Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 21-2004. A 63-year-old man with metastatic prostate carcinoma refractory to hormone therapy
    Donald S Kaufman
    Division of Medical Oncology, Department of Medicine, Massachusetts General Hospital, USA
    N Engl J Med 351:171-8. 2004
  2. doi request reprint Bladder cancer
    Donald S Kaufman
    Department of Medicine, the Claire and John Bertucci Center for Genitourinary Cancers, Massachusetts General Hospital, Boston, MA 02114, USA
    Lancet 374:239-49. 2009
    ..We discuss bladder preserving approaches, combination chemotherapy including new agents, targeted therapies, and advances in molecular biology...
  3. doi request reprint Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy
    Donald S Kaufman
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Urology 73:833-7. 2009
    ..To evaluate the safety, tolerance, protocol completion rate, tumor response rate, and patient survival of chemoradiotherapy for patients with muscle-invasive operable bladder cancer...
  4. pmc Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06
    Jason A Efstathiou
    Department of Radiation Oncology, Massachusetts General Hospital, 100 Blossom St, Cox 3, Boston, MA 02114, USA
    J Clin Oncol 27:4055-61. 2009
    ..We investigated late pelvic toxicity after chemoradiotherapy for patients treated on prospective protocols...
  5. doi request reprint Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase
    Timur Mitin
    Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114, USA
    Lancet Oncol 14:863-72. 2013
    ....
  6. doi request reprint Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience
    Jason A Efstathiou
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Eur Urol 61:705-11. 2012
    ..Whether organ-conserving treatment by combined-modality therapy (CMT) achieves comparable long-term survival to radical cystectomy (RC) for muscle-invasive bladder cancer (BCa) is largely unknown...
  7. doi request reprint The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
    Jennifer Y Wo
    Harvard Radiation Oncology Programm, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    BJU Int 104:179-83. 2009
    ....
  8. doi request reprint Nomograms predicting response to therapy and outcomes after bladder-preserving trimodality therapy for muscle-invasive bladder cancer
    John J Coen
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Int J Radiat Oncol Biol Phys 86:311-6. 2013
    ..We developed prognostic nomograms to predict the complete response rate, disease-specific survival, and likelihood of remaining free of recurrent bladder cancer or cystectomy...
  9. doi request reprint Bladder preservation: optimizing radiotherapy and integrated treatment strategies
    Raymond H Mak
    Department of Radiation, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    BJU Int 102:1345-53. 2008
    ..Future work will continue to refine the bladder-preserving approach to improve survival and local control...
  10. ncbi request reprint Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up
    William K Oh
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Urology 62:99-104. 2003
    ..Standard androgen deprivation strategies for prostate cancer typically lead to castrate levels of testosterone. One alternative is the use of finasteride and flutamide...
  11. doi request reprint Trimodality therapy for bladder conservation in treatment of invasive bladder cancer
    Timur Mitin
    Harvard Medical School, Massachusetts General Hospital, Department of Radiation Oncology, Boston, MA 02114, USA
    Curr Urol Rep 14:109-15. 2013
    ..In this review, the most recent advances in the field of bladder-preserving trimodality therapy are presented, and future directions for improving the outcomes are outlined...
  12. ncbi request reprint Association of statin use with improved local control in patients treated with selective bladder preservation for muscle-invasive bladder cancer
    Henry K Tsai
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Urology 68:1188-92. 2006
    ..To assess whether statin use improves local control (LC) in patients undergoing organ-preserving trimodality therapy for muscle-invasive bladder cancer...
  13. ncbi request reprint Case records of the Massachusetts General Hospital. Case 18-2007. A 54-year-old man with early-stage prostate cancer
    Donald S Kaufman
    Department of Hematology Oncology, Massachusetts General Hospital, USA
    N Engl J Med 356:2515-20. 2007
  14. pmc Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer
    M Dror Michaelson
    Division of Hematology and Oncology and Endocrine Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Oncol 25:1038-42. 2007
    ..Annual zoledronic acid increases BMD in postmenopausal women, but its efficacy in hypogonadal men is not known...
  15. ncbi request reprint Bladder-sparing approaches to invasive disease
    Jason A Efstathiou
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, 100 Blossom Street, Cox 3, Boston, MA 02114, USA
    World J Urol 24:517-29. 2006
    ..Future work will continue to optimize the bladder-sparing regimen while limiting toxicity...
  16. ncbi request reprint Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer
    M Dror Michaelson
    Department of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Cancer 107:530-5. 2006
    ..Atrasentan is an investigational agent that inhibits endothelin-1 receptor, resulting in decreased osteoblast activity...
  17. ncbi request reprint Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy
    Matthew R Smith
    Massachusetts General Hospital, Cancer Center, Boston MA 02114, USA
    J Clin Oncol 24:2723-8. 2006
    ..To assess the biologic activity of celecoxib, a selective cyclooxygenase-2 inhibitor, in men with recurrent prostate cancer using change in prostate-specific antigen (PSA) doubling time (PSADT) as the primary outcome variable...
  18. doi request reprint Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy
    Robert W Ross
    Center for Molecular Imaging Research, Massachusetts General Hospital, Boston, MA 02114, USA
    Clin Imaging 33:301-5. 2009
    ..Six (23%) of the 26 patients, previously believed to be node negative, tested lymph node positive by LNMRI. A total of nine positive lymph nodes were identified in these six patients, none of which were enlarged based on size criteria...
  19. doi request reprint Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer
    Jairam R Eswara
    Department of Urology, Massachusetts General Hospital, Boston, MA, USA
    J Urol 187:463-8. 2012
    ..Salvage cystectomy is reserved for those in whom combined modality therapy fails. We characterized complications associated with salvage cystectomy...
  20. ncbi request reprint Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 3-2004. A 57-year-old man with invasive transitional-cell carcinoma of the bladder
    Donald S Kaufman
    Division of Hematology Oncology, Massachusetts General Hospital, USA
    N Engl J Med 350:394-402. 2004
  21. ncbi request reprint Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy
    Matthew R Smith
    Division of Hematology and Medical Oncology, Massachusetts General Hospital, Boston 02114, USA
    Cancer 101:1569-74. 2004
    ....
  22. ncbi request reprint Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates--the Massachusetts General Hospital and Radiation Therapy Oncology Group experiences
    William U Shipley
    Department of Radiation Oncology, Harvard Medical School, Massachusetts General Hospital, Boston, MA 02138, USA
    Semin Radiat Oncol 15:36-41. 2005
    ..This preserves the urinary diversion options open to the surgeon as well as brings forward the time to a salvage procedure should it be needed...
  23. ncbi request reprint Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors
    Anthony L Zietman
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, 100 Blossom Street, Cox 302, Boston, MA 02114, USA
    J Urol 170:1772-6. 2003
    ..Concern exists about the function of the retained bladder after such therapy...
  24. ncbi request reprint Benchmarks achieved in the delivery of radiation therapy for muscle-invasive bladder cancer
    John J Coen
    Department of Radiation Oncology, Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114, USA
    Urol Oncol 25:76-84. 2007
    ..Radiation is a very effective palliative agent for patients with locally advanced or metastatic disease. It can palliate bleeding and pain for patients with local progression or alleviate pain from bony metastases...
  25. ncbi request reprint Transitional cell carcinoma of the upper uroepithelial tract
    M Dror Michaelson
    Massachusetts General Hospital, Dana Farber Cancer Institute, Boston, MA, USA
    Clin Adv Hematol Oncol 1:102-4; discussion 105. 2003
  26. doi request reprint Case records of the Massachusetts General Hospital. Case 15-2008. A 55-year-old man with an elevated prostate-specific antigen level and early-stage prostate cancer
    Michael J Barry
    Department of Medicine, Massachusetts General Hospital, USA
    N Engl J Med 358:2161-8. 2008
  27. ncbi request reprint Case records of the Massachusetts General Hospital. Case 6-2007. A 28-year-old man with a mass in the testis
    Donald S Kaufman
    Department of Hematology Oncology, Massachusetts General Hospital, USA
    N Engl J Med 356:842-9. 2007
  28. pmc Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer
    Philip J Saylor
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Urol 183:2200-5. 2010
    ..We applied the WHO/FRAX tool to men treated with androgen deprivation therapy for prostate cancer...
  29. ncbi request reprint A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer
    Donald S Kaufman
    Massachusetts General Hospital, Boston, MA, USA
    Urol Oncol 22:393-7. 2004
    ..Insufficient patients with poor renal function or prior therapy were accrued to reach conclusions regarding its utility in these subgroups...
  30. doi request reprint Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: a study of 45 cases
    Esther Oliva
    Pathology Department, Massachusetts General Hospital, Boston, MA 02118, USA
    Hum Pathol 44:860-6. 2013
    ..Our data suggest that a CK20(-) p53(-) CD44a panel proves to be very helpful (CK20 more reliable than p53 or CD44s) in the diagnosis of RAD-Ch...
  31. ncbi request reprint Case records of the Massachusetts General Hospital. Case 6-2006. A 71-year-old woman with urinary incontinence and a mass in the bladder
    Paula D Ryan
    Department of Medical Oncology, Massachusetts General Hospital, Boston, USA
    N Engl J Med 354:850-6. 2006
  32. ncbi request reprint Neoadjuvant doxil chemotherapy prior to androgen ablation plus radiotherapy for high-risk localized prostate cancer: feasibility and toxicity
    William K Oh
    Lank Center for Genitourinary Oncology, Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Am J Clin Oncol 26:312-6. 2003
    ..Neoadjuvant liposomal doxorubicin demonstrates no apparent activity and significant toxicity. New strategies are needed to improve outcomes in high-risk prostate cancer...